From the desk of Chris Lipinski, PhD

Starting a Conversation on Drug Discovery BiasesChris Lipinski, PhD

I’ve been thinking a lot lately about how to optimize for ligand affinity. Of course, this is a central theme of all drug discovery projects. At its core is the question of how physical and chemical relationships guide the interplay between the ligand, the protein target, and the water solvent. Existing measurements and techniques can directly reveal entropic and enthalpic contributions to this process, and ligand efficiency type of calculations can indirectly give similar information. In a somewhat convoluted process, after speaking at a Collaborative Drug Discovery (CDD) meeting in April, I began to think about how structure-based as opposed to high throughput screening (HTS) approaches might bias the compounds we develop, and how we might take advantage of those biases.

I’d like to start a larger conversation amongst drug discovery scientists to address these issues. To this end, I will be leading a live webinar event hosted by CDD, to begin to explore questions about whether the choice of the techniques that guide small molecule discovery efforts result in a systematic bias in the kinds of chemical leads we discover. We will discuss the benefits of different techniques and metrics, and especially as they relate to the differing goals in chemical biology and drug discovery. My hope is that if the webinar is provocative enough it might elicit listener ideas and help pull together some new insights in the broad drug discovery community. Please join me for what is sure to be a stimulating discussion.

Event details:
Date/Time: Wednesday, October 22, 2014 from 2-3pm ET (11am-12pm PT)

Where: Online webinar. Click here to register.

Posted 1:40 pm,

Anyone who has taken a general laboratory class knows that the lab manual has multiple protocols that one follows in order to complete each week’s assignment. However, while the class laboratory protocol has been thoroughly tested, academic and industry protocols are often changed and improved as new information is gleaned from previous experiments. A new […]

Posted 11:09 am,

Drug discovery, ever a challenge, can be likened to a tall structure. The upper stories rely on the stability of the floors below it, and a solid foundation is a must. No lofty heights will be reached when the base is not secure. And so, it is not a surprise that a drug discovery project […]

Posted 10:36 am,

“Innovation” is suddenly the word on everybody’s lips.  Pfizer launched “Centers for Therapeutic Innovation”, Johnson and Johnson followed with their “Innovation Centres” and now Merck followed with their “Innovation hubs”.  In fact, it happened so fast that many of us in the dusty halls of academia are still trying to get a grip on what’s […]

Posted 1:06 pm,

Sometimes, in tragic circumstances, a lesson can be learned and applied in unexpected ways. That appears to be the case with a rare disease that produces debilitating symptoms in children – but might also offer clues to developing a new class of antivirals. The particular disease, an extremely rare congenital disorder called CDG-IIb,  affects the […]

Posted 9:52 am,

We have recently discussed here how crowdfunding — donations from the general public in support of a cause, idea, or invention — has caught the attention of scientists seeking financial backing in an era of tight budgets. The brave new world of crowdfunding in science raises questions that defy easy answers. What is essential to […]

Posted 12:28 pm,

Connecting academic scientists to the global life science ecosystem Like everyone else, academic researchers are finding that funding sources are drying up and that they somehow must do more research work with less money. To do something about it, a group of Universities in Missouri and Kansas have teamed up with Assay Depot to create […]

Posted 11:39 am,

As we previously discussed, CRISPR-mania is sweeping the globe. (Okay, it might not be as big as Beatlemania, but more than a few life science researchers have probably squealed in delight.) The CRISPR system, derived from bacteria’s fight against viruses and tailored so that it can snip away genetic material in other organisms, has generated […]

Posted 2:26 pm,

It’s a sad story that everyone is familiar with: A patient takes one or more well-known cancer drugs, and they work — for a while. However, after the respite, the cancer comes roaring back, this time impervious to the once powerful effects of the cancer drugs. Many people would view the disease’s return with resignation […]

Posted 1:52 pm,

Over the course of this series so far we’ve looked at the role of the microbiome in two of the three major therapeutic areas targeted by drug discoverers.  Now comes the third and final segment and it’s a big one:  Cancer.  For many people the role of the microbiome in inflammation and metabolism is unsurprising.  Your […]

Posted 4:08 pm,